Filter posts

Senator Hatch Calls Out IPR Flaws

During today’s Senate Judiciary hearing, Senator Orrin Hatch addressed the dysfunctional interplay of the inter …

Orrin Hatch Is an Historic Figure in Biotechnology

As BIO CEO, everywhere I go – including Tokyo and Hong Kong last month – …

BIO to Senate Judiciary: Stop Abuses at PTO

Gamesmanship of the United States Patent and Trademark Office’s (PTO) Inter Partes Review (IPR) process …

Seventy Nine House Members Express Concern with H.R. 9

House leaders made the decision earlier this month to remove patent reform legislation from the …

Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?

In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first …